Breakout Ventures

Epana Bio focuses on treating autoimmune diseases by targeting their cellular origin, utilizing genomics and AI to develop tailored therapies.

Noetik is a comprehensive search directory platform that provides resources across multiple industries and topics, focusing on e-commerce and consumer products.

EnPlusOne Bio is a biotechnology company focused on enhancing RNA therapeutics through an innovative enzymatic platform that allows for unrestricted synthesis and manufacturing of RNA, enabling access to a broader design space with novel modifications.

Cytovale develops an innovative medical device for the rapid diagnosis of sepsis, utilizing their proprietary IntelliSep technology.

Immusoft is the world leader in the development of B cells as biofactories for therapeutic protein delivery, pioneering a novel approach called Immune System Programming (ISP™) to program B cells to produce personalized protein therapeutics for patients with rare diseases.

ZymoChem manufactures bio-based products with increased yields, utilizing proprietary Carbon Conserving (C2) microbes to convert renewable feedstocks into high-value materials. The company focuses on creating sustainable materials for hygiene, textiles, plastics, and coatings, aiming for a fossil-free future.

A-Alpha Bio is a biotechnology company harnessing synthetic biology and machine learning to measure, predict, and engineer protein-protein interactions. Their platforms, AlphaSeq and AlphaBind, enable the rapid and quantitative measurement of millions of protein-protein binding affinities and predict binding strength from sequence.

Passkey Therapeutics is focused on transforming pharmaceutical R&D by leveraging biological complexity to develop synergistic multifunctional therapeutics (SMThs) that target multiple biological pathways simultaneously.

Canaery is developing the world’s first nose-computer interface (NCI) that combines the natural sense of smell with advanced neurotechnology and artificial intelligence to interpret scents for various applications, including detection of contraband and disease diagnostics.

Twelve is a carbon transformation company that converts captured carbon dioxide into valuable chemicals, fuels, and other essential products typically made from fossil fuels.

Using immune organoids and AI to design drugs that work in people from the start, delivering safe and effective therapies without the need for traditional clinical trials.

Invests in early-stage life sciences companies, often backing founders when they are no more than an idea.

Founded by Bryan Johnson, invests in platforms and enabling technologies supporting inventors and scientists building programmable-biology solutions to rewrite life's operating systems and benefit humanity. OS Fund believes biology is programmable, and invests in platforms and enabling technologies (i.e. Ginkgo Bioworks).

Early-stage accelerator for synthetic biology and life sciences that gives scientist-founders lab independence with co-located BSL-rated wet labs and extended runway via SOSV integration reserving 75% for follow-ons. The world's first startup accelerator focused specifically on synthetic biology and life sciences, created to give scientists independence as founders rather than forcing them into traditional academic or big-pharma tracks. The program runs its own large wet-lab infrastructure where portfolio companies co-locate and build in BSL-rated labs owned by the fund, while providing an unusually long runway of capital through deep integration with SOSV's fund structure that reserves 75% for follow-on rounds.

Founded in 2002, +ND invests in disruptive technologies spanning life, physical, and data sciences, prioritizing opportunities driven by scientific convergence.

Flagship Pioneering operates as an "institutional innovation" model that internally originates 80-100 "explorations" per year through Flagship Labs based on "What if…?" hypotheses, then systematically evolves promising ideas through a staged company-creation funnel (Explorations → ProtoCos → NewCos → GrowthCos) that it fully founds, funds, and owns through early stages. The firm positions itself as principal founder rather than a traditional investor, building "bioplatform" companies organized around proprietary discovery engines and operating its own drug development unit, Pioneering Medicines, which partners directly with large pharmas like Pfizer and Novo Nordisk to co-create therapeutics.